
Zacks Small-Cap Research (Zacks SCR) values Protalix Biotherapeutics, a small Israeli drugmaker listed in the U.S., at nearly 500% higher than its current market price. The company stands out from peers because it already generates revenue and has recently paid off its debt. This, Zacks SCR points out, takes one…